A test for anti-TNF non-responders? Few alternative RA therapies available
This article was originally published in Scrip
Tumor necrosis factor (TNF) inhibitors, such as Amgen's Enbrel (etanercept) and AbbVie's Humira (adalimumab), are the biologics of choice to treat rheumatoid arthritis (RA) patients. But many people with the debilitating autoimmune disease don't respond to anti-TNF therapies, so what if you could identify patients early on who won't respond to those biologics?
You may also be interested in...
At ACR: Janssen reported data that show Celltrion’s Remicade biosimilar is not quite the same, but positive sirukumab results may not boost the Janssen and GSK biologic’s market prospects. Meanwhile, Corbus surged on mid-stage resunab results in systemic sclerosis, Janssen shared Phase II gesulkumab psoriasis results, Genentech eyes a new Actemra indication, and Xencor rose on interim Phase II data.
Public Company Edition: Xilio, Ventyx, MiNK and Context went public in the US and later traded at or above their initial public offering prices. Also, Sarepta raised $500m and Relay grossed $350m in new offerings, while Oncopeptides, Esperion, Zymergen and Ardelyx reorganized and cut jobs.
Avoro Capital, Holocene Advisors and Darwin Global say that Acceleron should sell later for a higher price based on forthcoming data or Merck should raise its bid above $180 per share.